#Gilead Sciences

Here’s how each undergraduate student plans to fight the HIV epidemic.

With funding by the three coordinating centers of the Gilead COMPASS Initiative

Here are the HIV treatment news stories with the most views this year.

Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.

It’s part of the People Organizing Positively initiative to help empower people living with HIV.

A recent study of people in British Columbia found, however, that people who inject drugs had lower cure rates.

Here are the top 20 philanthropic funders of HIV, according to an FCAA report, which also offers good news for the U.S. South and PrEP.

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

In a recent trial, Gilead’s regimen was highly successful in a group that included those with and without HIV coinfection.

Truvada drugmaker Gilead Sciences promotes HIV prevention and PrEP.

Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.

Biktarvy has a lower rate of adverse health events, according to 96-week data.

Located at the Rush Center, the SPOT builds upon the knowledge of people living with HIV.

Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.

Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.

Gilead Sciences has released 96-week results from an ongoing double-blinded study comparing the two regimens.